Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 5MEQ versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 5MEQ versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides glucose for cellular energy metabolism; sodium chloride and potassium chloride restore electrolyte balance and maintain osmotic gradients. Potassium is essential for neuronal conduction, muscle contraction, and acid-base regulation.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Intravenous infusion; rate determined by fluid and electrolyte requirements. Typical adult dose: 1000-2000 mL over 24 hours, providing 5 g dextrose, 0.2 g sodium chloride, and 5 mEq potassium chloride per 100 mL. Infusion rate not to exceed 25 mL/hr to avoid hyperkalemia.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Glucose: 2-3 hours (increased in renal impairment, diabetes); potassium: 12-24 hours (tissue redistribution); sodium/chloride: 20-30 minutes (rapid renal adjustment)
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Renal: >95% as free ions (K+, Na+, Cl-) and glucose metabolism products; biliary/fecal: <5%
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte